Crohn's disease (CD) is a chronic relapsing disorder of the gastrointestinal tract and
represents one of the main entities of inflammatory bowel disease (IBD). CD affects …

Crohn's disease can affect any part of the gastrointestinal tract; however, current European
and national guidelines worldwide do not differentiate between small-intestinal and colonic …

The cost of caring for patients with inflammatory bowel disease (IBD) continues to increase
worldwide. The cause is not only a steady increase in the prevalence of Crohn's disease …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

Abstract MicroRNAs [miRNAs], small non-coding RNAs, have recently been described as
crucial contributors to intestinal homeostasis. They can interact with the gut microbiota in a …

Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …

The importance of the gut microbiota in human health is currently well established. It
contributes to many vital functions such as development of the host immune system …

The gut barrier acts as a first line of defense in the body, and plays a vital role in nutrition
and immunoregulation. A layer of epithelial cells bound together via intercellular junction …

Increasing insights into the immunopathogenesis of inflammatory bowel diseases [IBD] have
led to the advent of targeted therapies that inhibit crucial mediators of the inflammatory …

Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs),
namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The …